Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis

Allergy and Asthma Proceedings

Volumn 32, Issue 2, 2011, Pages 159-167

  Meltzer, Eli O ^a   Shekar, Tulin ^b   Teper, Ariel A ^b  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOMETASONE FUROATE; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; BRONCHITIS; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HAY FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NASAL PRURITUS; NOSE CONGESTION; NOSE ULCER; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINORRHEA; SCHOOL CHILD; SCORING SYSTEM; SNEEZING; SORE THROAT; THROAT IRRITATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL OBSTRUCTION; NASAL SPRAYS; PLACEBOS; PREGNADIENEDIOLS; PRURITUS; RESEARCH DESIGN; RHINITIS, ALLERGIC, SEASONAL; SNEEZING; TREATMENT OUTCOME;

EID: 79953227004     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2011.32.3424     Document Type: Article

References (52)

1. 2LEN and AllerGen). Allergy 63(suppl 86):8-160, 2008.
2. Léger D, Annesi-Maesano I, Carat F, et al. Allergic rhinitis and its consequences on quality of sleep: An unexplored area. Arch Intern Med 166:1744-1748, 2006. (Pubitemid 44414463)
3. Meltzer EO, Nathan R, Derebery J, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: Findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 30:244-254, 2009.
4. Hiraki N, Suzuki H, Udaka T, et al. Snoring, daytime sleepiness, and nasal obstruction with or without allergic rhinitis. Arch Otolaryngol Head Neck Surg 134:1254-1257, 2008.
5. Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 22:1203-1210, 2006. (Pubitemid 44000740)
6. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 29:600-608, 2008.
7. European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 49:687-695, 1996.
8. Sakashita M, Hirota T, Harada M, et al. Prevalence of allergic rhinitis and sensitization to common aeroallergens in a Japanese population. Int Arch Allergy Immunol 151:255-261, 2010.
9. Antonicelli L, Micucci C, Voltolini S, et al. Relationship between ARIA classification and drug treatment in allergic rhinitis and asthma. Allergy 62:1064-1070, 2007. (Pubitemid 47220979)
10. Yariktas M, Doner F, and Demirci M. Rhinosinusitis among the patients with perennial or seasonal allergic rhinitis. Asian Pac Allergy Immunol 21:75-78, 2003. (Pubitemid 37406682)
11. Berrettini S, Carabelli A, Sellari-Franceschini S, et al. Perennial allergic rhinitis and chronic sinusitis: Correlation with rhinologic risk factors. Allergy 54:242-248, 1999. (Pubitemid 29185285)
12. Krouse JH. The unified airway - Conceptual framework. Otolaryngol Clin North Am 41:257-266, 2008.
13. Frieri M. Interaction between rhinitis and asthma: State of the art. Allergy Asthma Proc 24:385-393, 2003. (Pubitemid 38142602)
14. Frieri M. Inflammatory issues in allergic rhinitis and asthma. Allergy Asthma Proc 26:163-169, 2005. (Pubitemid 41328122)
15. Crown WH, Olufade A, Smith MW, et al. Seasonal versus perennial allergic rhinitis: Drug and medical resource use patterns. Value Health 6:448-456, 2003.
16. Allergies in America: A landmark survey of nasal allergy sufferers. Executive summary: Adult. Available online at www.mmcpub.com/scsaia/ AdultSummary.pdf; last accessed October 18, 2010.
17. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy 62(suppl 85):9-16, 2007. (Pubitemid 47561568)
18. Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 62(suppl 85):17-25, 2007. (Pubitemid 47561569)
19. Blaiss MS, Meltzer EO, Derebery MJ, et al. Patient and health-care-provider perspectives on the burden of allergic rhinitis. Allergy Asthma Proc 28(suppl 1):S4-S10, 2007.
20. Stull DE, Roberts L, Frank L, et al. Relationship of nasal congestion with sleep, mood, and productivity. Curr Med Res Opin 23:811-819, 2007. (Pubitemid 46631484)
21. Stull DE, Vernon MK, Canonica GW, et al. Using the Congestion Quantifier Seven-Item Test to assess change in patient symptoms and their impact. Allergy Asthma Proc 29:295-303, 2008.
22. Stull DE, Meltzer EO, Krouse JH, et al. The congestion quantifier five-item test for nasal congestion: Refinement of the congestion quantifier seven-item test. Am J Rhinol Allergy 24:34-38, 2010.
23. Price D, Bond C, Bouchard J, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: Management of allergic rhinitis. Prim Care Respir J 15:58-70, 2006. (Pubitemid 43155767)
24. Hebert JR, Nolop K, and Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex™) in seasonal allergic rhinitis: An active-and placebo-controlled study. Allergy 51:569-576, 1996.
25. Meltzer EO, Jalowayski AA, Orgel HA, et al. Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray. J Allergy Clin Immunol 102:39-49, 1998. (Pubitemid 28345783)
26. Berkowitz RB, Roberson S, Zora J, et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 20:167-172, 1999.
27. Mandl M, Nolop K, and Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group. Ann Allergy Asthma Immunol 79:370-378, 1997.
28. Schenkel E, LaForce C, and Gates D. Mometasone furoate nasal spray in seasonal allergic rhinitis: Effective in relieving ocular symptoms. Allergy Clin Immunol Int-J World Allergy Org 19:50-53, 2007. (Pubitemid 46909141)
29. Long AA. Findings from a 1000-patient Internet-based survey assessing the impact of morning symptoms on individuals with allergic rhinitis. Clin Ther 29:342-351, 2007. (Pubitemid 46667166)
30. Dibildox J. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials. J Allergy Clin Immunol 108:S54-S58, 2001. (Pubitemid 32678757)
31. Drouin M, Yang WH, Bertrand B, et al. Once daily mometasone furoate aqueous nasal is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 77:153-160, 1996. (Pubitemid 26274993)
32. Nayak AS. Mometasone furoate monohydrate nasal spray for the treatment of nasal congestion in allergic rhinitis. Expert Rev Clin Immunol 4:143-155, 2008. (Pubitemid 351903277)
33. Van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 55:116-134, 2000. (Pubitemid 30106016)
34. Lange B, Lukat K-F, Rettig K, et al. Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 95:272-282, 2005. (Pubitemid 41376798)
35. 1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 317: 1624-1629, 1998.
36. 1 receptor antagonists for the treatment of allergic rhinitis: A systematic review with meta-analysis. Ann Allergy Asthma Immunol 89:479-484, 2002.
37. Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: Olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 28:592-599, 2007.
38. Kaliner MA, Storms W, Tilles S, et al. Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 μg in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc 30:255-262, 2009.
39. Slavin RG, Spector SL, Bernstein IL, et al. The diagnosis and management of sinusitis: A practice parameter update. J Allergy Clin Immunol 116(suppl):S13-S47, 2005. (Pubitemid 41715240)
40. Greiner AN, and Meltzer EO. Pharmacologic rationale for treating allergic and nonallergic rhinitis. J Allergy Clin Immunol 5:985-998, 2006.
41. Meltzer EO. Clinical evidence for antileukotriene therapy in the management of allergic rhinitis. Ann Allergy Asthma Immunol 88(suppl):23-29, 2002. (Pubitemid 34408554)
42. Nathan RA, Yancey SW, Waitkus-Edwards K, et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest 128:1910-1920, 2005.
43. Martin BG, Andrews CP, and van Bavel JH. Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. Ann Allergy Asthma Immunol 96:851-857, 2006.
44. Rodrigo GJ, and Yañez A. The role of antileukotriene therapy in seasonal allergic rhinitis: A systematic review of randomized trials. Ann Allergy Asthma Immunol 96:779-786, 2006.
45. Anolik R, Pearlman D, Teper A, et al. Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. Allergy Asthma Proc 30:406-412, 2009.
46. Nathan RA. The pathophysiology, clinical impact, and management of nasal congestion in allergic rhinitis. Clin Ther 30:573-586, 2008. (Pubitemid 351680497)
47. LaForce C. Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol 103:S388-S394, 1999. (Pubitemid 29136282)
48. Scadding GK, Darby YC, and Austin CE. Effect of short-term treatment with fluticasone propionate nasal spray on the response to nasal allergen challenge. Br J Clin Pharmacol 38:447-451, 1994. (Pubitemid 24344033)
49. Frieri M, Therattil J, Chavarria V, et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 81:431-437, 1998. (Pubitemid 28555533)
50. Bende M, Carillo T, Vóna I, et al. A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann Allergy Asthma Immunol 88:617-623, 2002. (Pubitemid 36183816)
51. Marple BF. Targeting congestion in allergic rhinitis: The importance of intranasal corticosteroids. Allergy Asthma Proc 29:232-240, 2008.
52. Berger WE, Nayak AS, and Staudinger HW. Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis. Ann Pharmacother 39:1984-1989, 2005.